Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFUZOSIN HYDROCHLORIDE vs DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
Treatment of benign prostatic hyperplasia (BPH),Off-label: Management of ureteral stones (medical expulsive therapy)
treatment of symptomatic benign prostatic hyperplasia (BPH),combination therapy for BPH
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours).
Extensively metabolized in the liver, primarily via CYP3A4, to inactive metabolites.
Dutasteride is extensively metabolized by CYP3A4 and CYP3A5; tamsulosin is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4.
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces.
82-90% bound to human serum albumin and alpha-1-acid glycoprotein.
Dutasteride: >99.5% bound to albumin and alpha-1-acid glycoprotein. Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein.
Approximately 2.5-3.2 L/kg; indicates extensive extravascular distribution.
Dutasteride: Vd 300-500 L (total body, large tissue distribution). Tamsulosin: Vd 0.2 L/kg (approx 14-30 L, moderate distribution).
Oral immediate-release: 64% (first-pass metabolism); extended-release: 49% relative to immediate-release.
Dutasteride: Oral bioavailability ~60% (enhanced with food). Tamsulosin: Oral bioavailability ~30% (increased with food; formulation designed for consistent absorption).
For Cr Cl 30-49 m L/min: 10 mg once daily; for Cr Cl <30 m L/min: contraindicated.
No dosage adjustment is required for renal impairment. Tamsulosin is extensively metabolized and renally excreted as inactive metabolites; however, no specific GFR-based adjustments are recommended.
Child-Pugh A: 10 mg once daily; Child-Pugh B or C: contraindicated.
Dutasteride is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For mild to moderate hepatic impairment (Child-Pugh A or B), no dosage adjustment is recommended, but caution is advised.
Not established; safety and efficacy in children <18 years have not been studied.
Safety and efficacy in pediatric patients have not been established. Use is not recommended in patients under 18 years of age.
No specific dose adjustment recommended; monitor for orthostatic hypotension and dizziness.
No specific dose adjustment is required based on age alone. Elderly patients may be more sensitive to orthostatic hypotension from tamsulosin; monitor blood pressure and advise caution when rising from a seated or lying position.
None.
None
Risk of hypotension, especially orthostatic hypotension, particularly with dose initiation or increase,May cause syncope, especially in patients with predisposing factors (e.g., hypovolemia, concurrent antihypertensives),Use with caution in patients with hepatic impairment,Intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients on or previously treated with alpha-1 blockers,Should not be used in combination with other alpha-1 blockers
Orthostatic hypotension/syncope, especially with concurrent antihypertensives,Intraoperative floppy iris syndrome during cataract surgery,Risk of high-grade prostate cancer (increased Gleason score 8-10 with dutasteride),Hepatic impairment may increase exposure,Sexual dysfunction: decreased libido, erectile dysfunction, ejaculation disorders
Hypersensitivity to alfuzosin hydrochloride or any component of the formulation,Concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir),Moderate to severe hepatic impairment (Child-Pugh B or C)
Hypersensitivity to dutasteride, tamsulosin, or other 5α-reductase inhibitors,Women who are or may become pregnant (risk of fetal harm due to androgen inhibition),Severe hepatic impairment (Child-Pugh Class C),History of orthostatic hypotension
Take with food to reduce the risk of hypotension. Avoid grapefruit juice as it may increase alfuzosin levels. High-fat meals may alter absorption; consistency in meal timing is advised.
Absorption of tamsulosin is decreased when taken with food; however, the combination product should be taken 30 minutes after a meal to maintain consistent exposure. Avoid grapefruit juice as it may increase tamsulosin concentrations. No specific food interactions with dutasteride.
Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregnant women. First trimester: no evidence of fetal harm from animal data. Second and third trimesters: potential risk of maternal hypotension affecting uteroplacental perfusion; limited human data available.
Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosin has no known teratogenic risk. First trimester: Dutasteride exposure may cause feminization of male fetuses. Second and third trimesters: Risk persists; avoid use.
It is unknown if alfuzosin is excreted in human breast milk. The M/P ratio has not been determined. Caution is advised due to potential for adverse effects in nursing infants, including hypotension. Alternative agents with more safety data are preferred during breastfeeding.
Unknown if dutasteride or tamsulosin are excreted in human milk. Dutasteride is lipophilic and may appear in milk. Tamsulosin likely excreted. M/P ratio not available. Due to potential for adverse effects (e.g., hypotension), breastfeeding is not recommended during therapy.
No specific dose adjustments are recommended due to lack of pharmacokinetic data in pregnancy. However, increased plasma volume during pregnancy may reduce drug levels; clinical effect should be monitored. Use lowest effective dose if necessary, and avoid in patients with severe hypotension or hypovolemia.
No dose adjustment studies in pregnancy. Dutasteride should not be used; tamsulosin is not recommended. No pharmacokinetic changes requiring dose adjustment are established, but avoid use.
Alfuzosin is a selective alpha-1 adrenergic antagonist used for benign prostatic hyperplasia (BPH). It has fewer cardiovascular side effects than other alpha-blockers due to its higher affinity for alpha-1a receptors in the prostate. Do not use in patients with moderate to severe hepatic impairment. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Use with caution in patients with prolonged QT interval or on QT-prolonging drugs. Administer after the same meal each day to reduce first-dose syncope.
Dutasteride/tamsulosin is a fixed-dose combination for benign prostatic hyperplasia (BPH). Dutasteride is a 5α-reductase inhibitor that reduces prostate volume over months; tamsulosin is an α1-adrenoceptor antagonist providing rapid symptom relief. Do not split or crush capsules. Avoid use in women and children. Monitor for orthostatic hypotension, especially when initiating therapy. Assess for drug-drug interactions: CYP3A4 inhibitors (e.g., ketoconazole) increase dutasteride exposure; tamsulosin interacts with other α-blockers, antihypertensives, and PDE5 inhibitors. Counsel patients about risk of postural hypotension and syncope. Advise patients to avoid driving or hazardous activities until they know how the medication affects them. Dutasteride may cause sexual dysfunction (decreased libido, ejaculatory dysfunction, gynecomastia). Tamsulosin may cause intraoperative floppy iris syndrome during cataract surgery; inform ophthalmologist of use. Monitor serum PSA levels: dutasteride decreases PSA by ~50% after 6 months; establish new baseline. Do not use in patients with history of prostate cancer.
Take this medication immediately after a meal at the same time each day.,Avoid situations that may cause dizziness or fainting, especially after the first dose or when increasing dose.,Do not crush, chew, or open the tablet; swallow whole.,Do not drive or operate heavy machinery until you know how the medication affects you.,Inform your doctor if you experience severe dizziness, fainting, or irregular heartbeat.,Avoid alcohol, which can increase dizziness and blood pressure-lowering effects.,Do not take with other alpha-blockers or medications for erectile dysfunction without consulting your doctor.
Take this medication once daily, 30 minutes after the same meal each day.,Swallow capsules whole; do not crush, chew, or open.,Rise slowly from sitting or lying down to avoid dizziness or fainting.,Avoid driving or operating machinery until you know how the drug affects you.,Inform your doctor if you plan to have cataract surgery, as this drug may cause complications.,Do not donate blood while taking this medication, as it may harm a fetus if given to a pregnant woman.,Women who are pregnant or may become pregnant should not handle crushed or broken capsules.,Report any breast lumps, pain, or nipple discharge, as gynecomastia is possible.,Use condoms if your partner is pregnant, as dutasteride can be absorbed through skin contact with semen.,Keep all appointments for PSA blood tests; the test result will be lower than expected.,Do not take other alpha-blocker medications for blood pressure or prostate problems while on this drug unless prescribed.,Grapefruit juice may increase side effects; limit or avoid consumption.,Do not stop taking this medication suddenly without consulting your doctor.
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, can enhance the antihypertensive effect of Benidipine, a dihydropyridine calcium channel blocker. This occurs through additive vasodilation, potentially leading to excessive reductions in blood pressure. Clinically, patients may experience orthostatic hypotension, dizziness, or syncope, particularly during initial co-administration or dose adjustments."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, may potentiate the hypotensive effects of lamotrigine, an anticonvulsant. This interaction is primarily due to additive vasodilation, leading to an increased risk of orthostatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or with dose adjustments. Patients, especially those with cardiovascular comorbidities, should be monitored for blood pressure changes and symptoms of hypotension."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, reduces peripheral vascular resistance by blocking alpha-1 receptors on vascular smooth muscle. Pentolinium, a ganglionic blocker, inhibits sympathetic outflow by competitively blocking nicotinic acetylcholine receptors at autonomic ganglia, leading to pronounced hypotension. When combined, their additive vasodilatory effects can cause excessive hypotension, increased risk of syncope, dizziness, and potential cardiovascular collapse, especially during initial therapy or dose escalation."
"Tamsulosin, an alpha-1 adrenergic antagonist, and fosinopril, an ACE inhibitor, both lower blood pressure through distinct mechanisms, leading to additive hypotensive effects. This synergistic action increases the risk of orthostatic hypotension, dizziness, syncope, and falls, particularly at treatment initiation or dose escalation. The interaction is of clinical concern in elderly patients or those with volume depletion."
"Lofexidine, a central alpha-2 adrenergic agonist, reduces sympathetic outflow and can cause bradycardia and hypotension. Tamsulosin, an alpha-1 adrenergic receptor antagonist, also lowers blood pressure, especially orthostatic. Combined use leads to additive hypotensive effects, increasing risk of symptomatic bradycardia, orthostatic hypotension, syncope, and falls, particularly at therapy initiation or dose titration."
"The combination of tamsulosin and moexipril can lead to an increased risk of hypotension and orthostatic hypotension due to additive vasodilatory effects. Tamsulosin, an alpha-1 adrenergic antagonist, reduces peripheral vascular resistance, while moexipril, an ACE inhibitor, decreases angiotensin II production, further promoting vasodilation. This synergistic effect may cause symptomatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or during dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFUZOSIN HYDROCHLORIDE vs DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, answered by our medical review team.
ALFUZOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFUZOSIN HYDROCHLORIDE and DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE depend on the specific clinical indication. These are both Alpha-1 Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFUZOSIN HYDROCHLORIDE is: 10 mg orally once daily immediately after the same meal each day. Extended-release tablet.. The standard adult dose of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is: One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFUZOSIN HYDROCHLORIDE and DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFUZOSIN HYDROCHLORIDE is classified as Category C. Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregn. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is classified as Category A/B. Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.